GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » Other Current Receivables

Consun Pharmaceutical Group (HKSE:01681) Other Current Receivables : HK$126 Mil (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Other Current Receivables?

Consun Pharmaceutical Group's Other Current Receivables for the quarter that ended in Dec. 2023 was HK$126 Mil.

Consun Pharmaceutical Group's quarterly Other Current Receivables declined from Dec. 2022 (HK$147.88 Mil) to Jun. 2023 (HK$54.09 Mil) but then increased from Jun. 2023 (HK$54.09 Mil) to Dec. 2023 (HK$125.67 Mil).

Consun Pharmaceutical Group's annual Other Current Receivables declined from Dec. 2021 (HK$179.97 Mil) to Dec. 2022 (HK$147.88 Mil) and declined from Dec. 2022 (HK$147.88 Mil) to Dec. 2023 (HK$125.67 Mil).


Consun Pharmaceutical Group Other Current Receivables Historical Data

The historical data trend for Consun Pharmaceutical Group's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Other Current Receivables Chart

Consun Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.65 11.72 179.97 147.88 125.67

Consun Pharmaceutical Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 179.97 29.05 147.88 54.09 125.67

Consun Pharmaceutical Group Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Consun Pharmaceutical Group Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Consun Pharmaceutical Group (HKSE:01681) Business Description

Traded in Other Exchanges
Address
71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Executives
An Yubao 2101 Beneficial owner
Li Qian 2101 Beneficial owner
Central Success Developments Limited 2101 Beneficial owner
Aali Resources Limited 2201 Interest of corporation controlled by you
Bos Trustee Limited 2301 Trustee
Zhang Lihua 2202 Interest of your spouse
An Meng 2101 Beneficial owner
Double Grace International Limited 2101 Beneficial owner
Bos Trustee Limited As Trustee 2201 Interest of corporation controlled by you

Consun Pharmaceutical Group (HKSE:01681) Headlines

No Headlines